Brock O'Neil,
MD
Languages Spoken: English, Italian
Brock O’Neil, MD is an assistant professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.
Clinical Locations
801-585-0250
Specialties
Board Certification and Academic Information
| Academic Departments | Surgery
-
Assistant Professor |
| Academic Divisions | Urology |
| Board Certification | American Board of Urology |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.3/ 5
Care provider's concern for questions & worries
4.7/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
July 16, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
June 30, 2021
HUNTSMAN CANCER CENTER
the doctor was great it was the wait tome
UofU Patient
June 30, 2021
HUNTSMAN CANCER CENTER
We just couldn't have asked for any better care.
UofU Patient
June 18, 2021
HUNTSMAN CANCER CENTER
Great people
UofU Patient
June 09, 2021
HUNTSMAN CANCER CENTER
Dr. O'neil is exceptional.
UofU Patient
June 06, 2021
HUNTSMAN CANCER CENTER
they really care for there patients truly
UofU Patient
June 05, 2021
HUNTSMAN CANCER CENTER
Very professiona?
UofU Patient
May 29, 2021
HUNTSMAN CANCER CENTER
explained everything, didn't rush and was very positive minded. put me at ease.
UofU Patient
May 23, 2021
HUNTSMAN CANCER CENTER
It now appears that Dr. O'Neil and his staff have saved my life. So whether or not I waited in the exam room for 5 minutes is not real important to me these days. Dr. O'Neil's honesty with me and his concern for my health have been outstanding.
UofU Patient
May 13, 2021
HUNTSMAN CANCER CENTER
very professional
UofU Patient
May 05, 2021
HUNTSMAN CANCER CENTER
All the staff was exceptional.
UofU Patient
April 24, 2021
HUNTSMAN CANCER CENTER
Very professional listens and ask questions gives you the feeling things will be ok that my doctor cares.
UofU Patient
April 09, 2021
HUNTSMAN CANCER CENTER
Dr O'Neil is wonderful
UofU Patient
April 09, 2021
HUNTSMAN CANCER CENTER
This was a very positive experience even though it involved cancer. I feel like everyone truely cared about my well being.
UofU Patient
March 29, 2021
HUNTSMAN CANCER CENTER
ok
UofU Patient
March 21, 2021
HUNTSMAN CANCER CENTER
Very professional
UofU Patient
March 19, 2021
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
March 13, 2021
HUNTSMAN CANCER CENTER
Doc seemed to be in a hurry.
UofU Patient
March 12, 2021
HUNTSMAN CANCER CENTER
It would have been helpful to explain the Rx instructions during our visit. Because the instructions were unusual, I questioned my pharmacist. He also found them unusual and simply referred me to my doctor. I messaged Dr O'Neal after picking up the prescription to ask for clarification which he then provided.
UofU Patient
March 05, 2021
HUNTSMAN CANCER CENTER
Given what I had the staff was super supportive
UofU Patient
March 03, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
February 28, 2021
HUNTSMAN CANCER CENTER
Everyone was great
UofU Patient
February 19, 2021
HUNTSMAN CANCER CENTER
Now that we're on a schedule and not just figuring out what's wrong, this is a smooth process.
UofU Patient
February 07, 2021
HUNTSMAN CANCER CENTER
All my questions were answered
UofU Patient
January 29, 2021
HUNTSMAN CANCER CENTER
Dr. O'Neill was honest and caring about my situation every step of the way. And his surgical skills kept my pain and recovery times to an absolute minimum. Quite a doctor and quite a team!
UofU Patient
January 27, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
January 17, 2021
HUNTSMAN CANCER CENTER
excellent
UofU Patient
January 10, 2021
HUNTSMAN CANCER CENTER
excellent experience
UofU Patient
December 20, 2020
HUNTSMAN CANCER CENTER
very professional
UofU Patient
December 11, 2020
HUNTSMAN CANCER CENTER
Once I spoke to the resident and the doctor, the care and empathy was lovely. Thank you.
UofU Patient
November 14, 2020
HUNTSMAN CANCER CENTER
Always a very good experience with Dr. O Neil
UofU Patient
November 07, 2020
HUNTSMAN CANCER CENTER
Dr. O'Neil was very clear in explaining all my treatment options and risks/benefits of each.
UofU Patient
October 11, 2020
HUNTSMAN CANCER CENTER
They were very reassuring that the current course of treatment with my current doctor is what's best for me right now.
UofU Patient
September 27, 2020
HUNTSMAN CANCER CENTER
it was a matter of proceeding with a surgery or waiting for better information
UofU Patient
September 18, 2020
HUNTSMAN CANCER CENTER
dr O'Neill is the best
UofU Patient
September 16, 2020
HUNTSMAN CANCER CENTER
Exceptional. Dr. Brock O'Neil and his entire staff were amazing with all concerns.
UofU Patient
August 24, 2020
HUNTSMAN CANCER CENTER
I know Dr's are busy... would like to have had a little more time with the surgeon.
UofU Patient
August 01, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
July 24, 2020
HUNTSMAN CANCER CENTER
I am blessed to have crossed paths with my provider! he and his team have been more than amazing and have honestly saved my life!
UofU Patient
July 19, 2020
HUNTSMAN CANCER CENTER
this is my issue. when they called and told me it was via the web and i told them about the lump they said we still had to do a web. now i have to wait 3 more months to get it checked
UofU Patient
July 13, 2020
HUNTSMAN CANCER CENTER
professional
UofU Patient
June 21, 2020
HUNTSMAN CANCER CENTER
Dr O'Neil is obviously very competent at what he does so was his PA
UofU Patient
June 14, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
May 22, 2020
HUNTSMAN CANCER CENTER
I saw both a pa and doctor and treated very well.
UofU Patient
May 07, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
May 03, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
April 19, 2020
HUNTSMAN CANCER CENTER
Complete, candid, helpful, sobering
UofU Patient
March 06, 2020
HUNTSMAN CANCER CENTER
excellent experience
UofU Patient
February 17, 2020
HUNTSMAN CANCER CENTER
I was very pleased with Dr. ONeil. I wasnt able to get in with the Urologist my cousin had worked with and I hoped I would like Dr. ONeil as well. I was not disappointed. He is genuine and answered my questions and concerns, for which I am grateful.
UofU Patient
February 16, 2020
HUNTSMAN CANCER CENTER
good
Brock O’Neil, MD is an assistant professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.
Academic Locations
Huntsman Cancer Hospital
801-587-4282
Research Statement
Dr. O’Neil co-directs the Urologic Oncology Research group. His research interests include measuring outcomes important to patients, improving the quality of surgical care for cancer, and understanding the effects of payment reform on cancer treatment. Dr. O’Neil is also interested in understanding the sociological forces that shape physician behavior and ultimately patient outcomes.
He is funded through the National Cancer Institute to study drivers of low-value cancer care with a focus on designing interventions to reduce this unnecessary care. He has a particular interest in improving the value of prostate cancer screening and runs a clinic that focuses on screening men who carry genetic mutations that place them at high risk for developing prostate cancer. He also receives NCI funding as part of a national study (CEASAR) to understand the impact of various prostate cancer treatments on patient outcomes.
Dr. O’Neil is a member of the Huntsman@Home evaluation committee, which aims to understand whether a novel hospital at home program provides value for patients treated at Huntsman. He also serves a Principle Investigator of several trials at Huntsman including the SOAR trial (Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer).
He has authored multiple book chapters, articles, commentaries, and abstracts and has published in peer-reviewed journals including the Journal of National Cancer Institute, JAMA Surgery, and the Journal of Urology.
Board Certification and Academic Information
| Academic Departments | Surgery
-
Assistant Professor |
| Academic Divisions | Urology |
| Board Certification | American Board of Urology |
Education History
| Fellowship | Vanderbilt University Urologic Oncology and Health Services Research Fellow |
| Residency | University of Utah Urology Resident |
| Internship | University of Utah General Surgery Intern |
| Professional Medical | University of Rochester School of Medicine & Dentistry Doctor of Medicine with Distinction in Research M.D. |
| Undergraduate | Brigham Young University Exercise Science, Minor in Sociology B.S. |
Selected Publications - Journal Articles
Journal Article
- Hunt TC, Ambrose JP, Haaland B, Kawamoto K, Dechet CB, Lowrance WT, Hanson HA, ONeil BB (2021). Decision fatigue in low-value prostate cancer screening. Cancer, 127(18), 3343-3353.
- Dorff TB, ONeil B, Hoffman KE, Lin DW, Loughlin KR, DallEra M (2021). 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol Oncol, 39(9), 521-527.
- Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, 39(23), 2586-2593.
- Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2021). Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. (Epub ahead of print) Urol Oncol.
- Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2021). Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer, 127(11), 1912-1925.
- Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, ONeil BB, Tward JD (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precis Oncol, 5.
- Stone BV, Laviana AA, Luckenbaugh AN, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Joyce DD, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. J Urol, 205(3), 761-768.
- Lange SM, Ambrose JP, Flynn MC, Lowrance WT, Hanson HA, ONeil BB (2021). Prostate-specific antigen testing among young men: an opportunity to improve value. Cancer Med, 10(6), 2075-2079.
- Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. J Urol, 204(6), 1236-1241.
- Huelster HL, Laviana AA, Joyce DD, Huang LC, Zhao Z, Koyama T, Hoffman KE, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg M, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urol Oncol, 38(12), 930.e23-930.e32.
- Klett DE, ONeil B (2020). Transurethral Resection of a Bladder Tumor in Pregnancy: Decidual Reaction Bladder Endometriosis. J Endourol Case Rep, 6(3), 132-134.
- Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol, 78(2), 248-255.
- Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5.
- Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6.
- Leiser CL, Taddie M, Hemmert R, Richards Steed R, VanDerslice JA, Henry K, Ambrose J, ONeil B, Smith KR, Hanson HA (2020). Spatial clusters of cancer incidence: analyzing 1940 census data linked to 1966-2017 cancer records. Cancer Causes Control, 31(7), 609-615.
- Oswald N, Lin T, Haaland B, Flynn M, Kawamoto K, Cooney KA, Lowrance W, Hanson HA, ONeil B (2020). Factors associated with appropriate and low-value PSA testing. Cancer Epidemiol, 66, 101724.
- Leiser CL, Anderson RE, Martin C, Hanson HA, ONeil B (2020). Combining Drive Time and Urologist Density to Understand Access to Urologic Care. Urology, 139, 78-83.
- Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926.
- Jalali A, Martin C, Nelson RE, Vanneman ME, Martin BI, Cooney KA, Waitzman NJ, ONeil B (2019). Provider Practice Competition and Adoption of Medicare's Oncology Care Model. Med Care, 58(2), 154-160.
- Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA (2020). Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323(2), 149-163.
- Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2019). Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes? J Urol, 202(6), 1150-1158.
- Hanson HA, Martin C, ONeil B, Leiser CL, Mayer EN, Smith KR, Lowrance WT (2019). The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol, 202(6), 1209-1216.
- Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098.
- Martin C, ONeil B, Lowrance W, Leiser C, Mayer E, Smith K, Hanson H (2019). The Relative Importance of Race Compared to Healthcare and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol.
- Laviana A, Hernandez A, Zhao Z, Huang L, Koyama T, Conwill R, Feurer I, Hoffman K, Goodman M, Hamilton A, Wu X, Paddock L, Stroup A, Cooperberg M, Hashibe M, ONeil B, Penson D, Barocas D (2019). Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes? J Urol.
- Martin C, Haaland B, Tward AE, Dechet C, Lowrance W, Stephenson RA, Hanson H, ONeil B (2018). Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making. J Urol, 201(4), 751-758.
- Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039.
- ONeil B, Martin C, Kapron A, Flynn M, Kawamoto K, Cooney KA (2018). Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer Epidemiol, 56, 112-117.
- Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533.
- ONeil B, Tyson M, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The influence of provider characteristics and market forces on response to financial incentives. Am J Manag Care, 23(11), 662-667.
- ONeil BB, Hoffman KE, Tasuki K, et al (2017). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiotherapy Versus External Beam Radiotherapy of the Mid-1990's for Localized Prostate Cancer. Urol Pract.
- Martin C, Leiser CL, ONeil BB, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A population-Based Case-Control Study. J Natl Cancer Inst.
- ONeil B, Maughan B (2017). A More Common Massive Retroperitoneal Mass. JAMA Surg, 152(8), 802-803.
- ONeil B, Tyson MD, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The Influence of Provider Characteristics and Market Forces on Response to Financial Incentives. Am J Manag Care.
- Sohn W, Graves AJ, Tyson MD, ONeil BB, Chang SS, Ni D, Barocas DA, Penson DF, Resnick MJ (2016). An Empiric Evaluation of the Effect of Variation in Intensity of Follow-Up for Surgically Treated Renal Neoplasms: Estimating Value in Survivorship Care. J Urol.
- ONeil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 195(2), 321-9.
- ONeil BB, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2015). Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. J Natl Cancer Inst, 108(2).
- ONeil BB, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, and Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 196.
- ONeil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO (2014). Climacturia after definitive treatment of prostate cancer. J Urol, 191(1), 159-63.
Conference Proceedings
Editorial
Letter
- Hanson HA, Martin C, Leiser CL, ONeil B, Smith KR (2018). Response to K. Hemminki et al. [Letter to the editor]. J Natl Cancer Inst, 110(11), 1279.
- ONeil B, Lowrance WT, Heilbrun ME (2017). PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors. [Letter to the editor]. JAMA, 318(16), 1614.
Abstract
- ONeil B, Anderson R, Martin C, Leiser C, Hanson H (2019). A Novel Approach to Identify Disparities in Access to Urologic Care Based Upon Driving TIme [Abstract].
- Greenberg S, Tward J, Cooney K, Pappas L, ONeil B (2019). Germline genetic testing in men with prostate cancer: clinical characteristics and testing outcomes in a newly indicated population [Abstract].
- Armstrong J, Martin C, ONeil B, Dechet C, Morton K, Lowrance W (2018). Fluciclovine PET CT Detection of Biochemical Recurrent Prostate Cancer at Specific PSA Thresholds After Definitive Treatment [Abstract]. WSAUA.
- Jalali A, Nelson R, Vanneman M, Martin C, Martin B, Waitzman N, ONeil BB (06/25/2018). Provider Practice Competition and Adoption of Medicare's Oncology Care Model [Abstract]. AcademyHealth.
- Hanson H, Leiser C, Martin C, ONeil BB, Lowrance W, Alter O, Gupta S, Kohlman W, Greenberg W, Smith K, Camp N (04/2018). Redefining the Bladder Cancer Phenotype Using Patterns of Familial Risk [Abstract]. Journal of Urology, 199(4).
- Martin C, ONeil BB, Kapron A, Kawamoto K, Lowrance W, Flynn M, Cooney K (04/01/2018). Rate of Discordant PSA Testing Among Varied Guidelines: Identifying Targetable Inefficiencies in Our Health System [Abstract]. Journal of Urology, 199(4).
- Martin CM, ONeil BB, Kapron A, Flynn M, Kawamoto K, Lowrance WT, Cooney K (2017). Measuring PSA Screening Quality at the Health System Level: Potental Areas for Improvement [Abstract]. Society of Urologic Oncology.